氧化应激调节左心室PDE5表达在失败的心脏
Zhongbing Lu1, Xin Xu, Xinli Hu
1Cardiovascular Division, University of Minnesota, Minneapolis, MN 55455, USA.
Circulation
|March 24, 2010
概括
氧化应激会提高心脏衰竭中的固酶5型 (PDE5) 表达. 减少氧化应激或抑制PDE5可以防止心力衰竭和缩.
科学领域:
- 心血管研究研究心血管研究
- 分子心脏病学分子心脏病学
- 心脏衰竭病理生理学 病理生理学
背景情况:
- 固酶5型 (PDE5) 抑制在心力衰竭中显示出好处,表明其在充血性心力衰竭 (CHF) 中的作用.
- 氧化压力与心血管疾病的进展有关.
研究的目的:
- 调查氧化应激是否会增加心脏肌细胞中PDE5的表达.
- 确定高PDE5是否有助于CHF的发展.
主要方法:
- 在人类CHF样本和TAC诱导的小鼠CHF模型中评估心肌PDE5表达和分布.
- 使用超氧化物失调酶 (SOD) 模仿M40401和西尔代纳菲尔进行干预.
- 检查了氧化应激标志物,如3'-尼铁和4-氨.
主要成果:
- 肌肉中PDE5蛋白在人心慢性心力衰竭中显著增加 (~4.5倍),并与氧化应激标志物相关.
- 在CHF中,PDE5表达在心脏肌细胞和血管光滑肌中增加.
- M40401减弱PDE5增加并保护CHF;西尔代纳菲尔抑制PDE5,减少氧化应激和CHF.
结论:
- 心肌氧化应激是心脏衰竭中增加PDE5表达的关键驱动因素.
- 减少氧化应激或抑制PDE5提供了对压力过载引起的CHF和高的心脏保护.
相关概念视频
Pathophysiology of Heart Failure
4.8K
Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
4.8K
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
1.9K
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
1.9K
Ischemic Heart Disease: Overview
3.8K
Ischemic heart disease occurs when the heart's blood supply dwindles, causing an ominous lack of oxygen and nutrients. This deficiency, stemming from reduced or obstructed blood flow, spells danger, leading to heart muscle damage and dysfunction.
Atherosclerosis, the primary malefactor, orchestrates this dangerous condition. It manifests as the accumulation of fatty deposits, akin to insidious plaques, within arterial walls. As time elapses, these plaques metamorphose, hardening and...
Atherosclerosis, the primary malefactor, orchestrates this dangerous condition. It manifests as the accumulation of fatty deposits, akin to insidious plaques, within arterial walls. As time elapses, these plaques metamorphose, hardening and...
3.8K
Mitral Stenosis I: Introduction
1.8K
Mitral Valve Stenosis (MVS) is a heart condition where the mitral valve narrows, impeding blood circulation from the left atrium to the left ventricle. The etiology and pathophysiology of this condition are multifaceted, leading to a cascade of cardiovascular complications.Causes of Mitral Valve StenosisRheumatic Heart Disease: It is the main cause of mitral valve stenosis, particularly in developing nations. This condition arises from rheumatic fever, an inflammatory illness resulting from...
1.8K
Coronary Artery Disease II: Pathophysiology
1.1K
Coronary Artery Disease (CAD) originates from a series of events that impair the function of coronary arteries, the blood vessels responsible for delivering oxygen-rich blood to the heart muscle. The pathophysiology of CAD is closely linked to atherosclerosis, a chronic inflammatory and lipid-driven condition affecting the vascular endothelium.1. Endothelial DamageThe process begins with damage to the vascular endothelium, which serves as a protective barrier between the blood and the vessel...
1.1K
Heart Failure II: Pathophysiology
1.9K
Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
1.9K


